SMS Pharmaceuticals Limited (IN:SMSPHARMA)
:SMSPHARMA
Want to see IN:SMSPHARMA full AI Analyst Report?
SMSPHARMA Stock Chart & Stats
₹325.40
-₹5.32(-2.16%)
At close: 4:00 PM EST
₹325.40
-₹5.32(-2.16%)
Day’s Range― - ―
52-Week Range₹208.20 - ₹446.50
Previous CloseN/A
Volume71.57K
Average Volume (3M)105.50K
Market Cap
₹35.70B
Enterprise Value₹37.97B
Total Cash (Recent Filing)₹1.02B
Total Debt (Recent Filing)₹3.24B
Price to Earnings (P/E)33.6
Beta1.55
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)9.69
Shares Outstanding93,652,030
10 Day Avg. Volume15,241
30 Day Avg. Volume105,503
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)4.36
Price to Sales (P/S)3.87
P/FCF Ratio-37.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API Manufacturing ModelA focused B2B API manufacturing model creates durable, repeatable revenue from formulators and drug makers. Supplying both domestic and export markets diversifies demand channels, while bulk-API production benefits from scale, long-term contracts and higher switching costs versus finished-dose competition.
Improving Leverage / Balance SheetNotable debt reduction and a stronger equity base materially improve financial resilience. Lower leverage reduces interest burden and refinancing risk, expanding capacity for capex or working-capital needs and providing a firmer footing to withstand cyclical downturns in API demand.
Return To Profitability And Positive Revenue TrendRecovery from a loss year to consistent profits and modest revenue growth signals operational improvement and market traction. Sustained earnings support reinvestment, capacity maintenance and longer-term customer relationships, underpinning more reliable cash generation if volatility eases.
Bears Say
Weak Cash Generation / Negative Free Cash FlowRecurring negative free cash flow despite reported profits is a structural weakness. Low conversion of earnings to cash constrains funding for capex, working capital and dividends, increases reliance on external financing, and raises liquidity risk if margins normalize or sales soften.
Volatile Margins And Uneven Earnings PowerWide swings in margins reflect exposure to raw material costs, product mix shifts and pricing pressure. This earnings volatility reduces predictability of returns, complicates capacity planning and raises the chance that short-term cost swings will erode profitability and cash if not managed.
Profitability Sensitivity Could Pressure Balance SheetHistoric inconsistency in returns means the improving balance sheet is conditional. If the earnings cycle reverses, weaker profits combined with modest cash conversion could force more debt or asset sales, undermining recent leverage gains and limiting strategic flexibility.
SMS Pharmaceuticals Limited News
SMSPHARMA FAQ
What was SMS Pharmaceuticals Limited’s price range in the past 12 months?
SMS Pharmaceuticals Limited lowest stock price was ₹208.20 and its highest was ₹446.50 in the past 12 months.
What is SMS Pharmaceuticals Limited’s market cap?
SMS Pharmaceuticals Limited’s market cap is ₹35.70B.
When is SMS Pharmaceuticals Limited’s upcoming earnings report date?
SMS Pharmaceuticals Limited’s upcoming earnings report date is Aug 10, 2026 which is in 76 days.
How were SMS Pharmaceuticals Limited’s earnings last quarter?
SMS Pharmaceuticals Limited released its earnings results on May 22, 2026. The company reported ₹3.58 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.58.
Is SMS Pharmaceuticals Limited overvalued?
According to Wall Street analysts SMS Pharmaceuticals Limited’s price is currently Overvalued.
Does SMS Pharmaceuticals Limited pay dividends?
SMS Pharmaceuticals Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of 0.13%. See more information on SMS Pharmaceuticals Limited dividends here
What is SMS Pharmaceuticals Limited’s EPS estimate?
SMS Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Pharmaceuticals Limited have?
SMS Pharmaceuticals Limited has 93,652,030 shares outstanding.
What happened to SMS Pharmaceuticals Limited’s price movement after its last earnings report?
SMS Pharmaceuticals Limited reported an EPS of ₹3.58 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10.537%.
Which hedge fund is a major shareholder of SMS Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:SMSPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral APIs. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.
Technical Analysis
Gland Pharma Ltd.
―
Kopran Limited
―
Marksans Pharma Limited
―
NGL Fine-Chem Ltd.
―
Senores Pharmaceuticals Ltd.
―